Lercanidipine (Rec 15/2375): A Novel 1,4‐Dihydropyridine Calcium Antagonist for Hypertension

Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension

“…Its high lipophilicity sets off a slow accumulation of active concentrations and persistent membrane binding [30]. In a wide range of pre-clinical studies and controlled clinical trials it was shown to exert an effective, long-lasting and vascularselective calcium entry-blocking activity, while sympathetic activation and reflex tachycardia were not induced [31][32][33].…”

Neuroprotective Effect of Lercanidipine- A Novel Calcium Channel Blocker in Albino Mice

“…Lercanidipine, a newer generation DHP CCB, is used for treatment of mild to moderate hypertension. It differs from other DHP by its unique properties like high flexibility, lipophilicity, longer duration of action and tissue selectivity [12]. Literature review also provided insights about the stable pharmacokinetics, minimal adverse effects, better tolerability and safety profile exhibited by lercanidipine…”

Synthesis and calcium channel antagonist activity of novel 1,4-dihydropyridine derivatives possessing 4-pyrone moieties

“…The 1,4-dihydropyridine heterocyclic ring is a common feature of various bioactive compounds such as antihypertensive, antitumor, vasodilator, bronchodilator, anti atherosclerotic, hepatoprotective, anti mutagenic, and anti diabetic agents (Janis and Triggle, 1983;Sausins and Duburs, 1988;Mager et al, 1992;Manhold et al, 1992). A number of 1,4-dihydropyridine calcium channel antagonists have been introduced as potential drugs for the treatment of cardiovascular disease (Gordeev et al, 1996;Testa et al, 1997;Triggle 2003a, b;Baranda et al, 2006;Gupta and Misra, 2008). In particular, dihydropyridine druges such as Nifedipine (1, Fig.…”